Form 4 for IBO IMPACT BIOMEDICAL INC.
Accepted 2025-04-04 00:00:00 ET · period of report 2025-04-02 · accession 0001641172-25-002819 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MI | 2025-04-04 | 2025-04-02+ | IBO | Alset Inc. | 10% | S - Sale | $0.6636 | -1.69M | 0 | -100% | -$1.12M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common stock | 2025-04-02 | S | D | 300,000 | $0.58 | 553,904 | I See footnote | — | — | (F1) On April 2, 2025, Alset International Limited sold 300,000 shares of the Issuer's common stock at a weighted average sale price of $0.581. This transaction was executed in multiple trades at prices ranging from $0.551 to $0.607. The reporting person hereby undertakes to provide, upon request of the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. (F8) Mr. Chan is, personally and through an entity he controls, the majority shareholder of Alset Inc., and the Chairman and Chief Executive Officer of Alset Inc. Alset International Limited is a majority owned subsidiary of Alset Inc. Mr. Chan now may be deemed to be the beneficial owner of the 351,555 shares of common stock held by Alset International Limited. |
| 2 | Common | Common stock | 2025-04-02 | S | D | 200,000 | $0.67 | 353,904 | I See footnote | — | — | (F2) On April 2, 2025, Alset International Limited sold 200,000 shares of the Issuer's common stock at a weighted average sale price of $0.674. This transaction was executed in multiple trades at prices ranging from $0.67 to $0.80. The reporting person hereby undertakes to provide, upon request of the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. (F8) Mr. Chan is, personally and through an entity he controls, the majority shareholder of Alset Inc., and the Chairman and Chief Executive Officer of Alset Inc. Alset International Limited is a majority owned subsidiary of Alset Inc. Mr. Chan now may be deemed to be the beneficial owner of the 351,555 shares of common stock held by Alset International Limited. |
| 3 | Common | Common stock | 2025-04-02 | S | D | 2,349 | $0.67 | 351,555 | I See footnote | — | — | (F3) On April 2, 2025, Alset International Limited sold 2,349 shares of the Issuer's common stock at a weighted average sale price of $0.673. The reporting person hereby undertakes to provide, upon request of the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. (F8) Mr. Chan is, personally and through an entity he controls, the majority shareholder of Alset Inc., and the Chairman and Chief Executive Officer of Alset Inc. Alset International Limited is a majority owned subsidiary of Alset Inc. Mr. Chan now may be deemed to be the beneficial owner of the 351,555 shares of common stock held by Alset International Limited. |
| 4 | Common | Common stock | 2025-04-02 | S | D | 382,427 | $0.58 | 351,631 | I See footnote | — | — | (F4) On April 2, 2025, Alset Inc. sold 382,427 shares of the Issuer's common stock at a weighted average sale price of $0.583. This transaction was executed in multiple trades at prices ranging from $0.57 to $0.63. The reporting person hereby undertakes to provide, upon request of the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. (F8) Mr. Chan is, personally and through an entity he controls, the majority shareholder of Alset Inc., and the Chairman and Chief Executive Officer of Alset Inc. Alset International Limited is a majority owned subsidiary of Alset Inc. Mr. Chan now may be deemed to be the beneficial owner of the 351,555 shares of common stock held by Alset International Limited. |
| 5 | Common | Common stock | 2025-04-03 | S | D | 351,631 | $0.58 | 0 | I See footnote | — | — | (F5) On April 3, 2025, Alset Inc. sold 351,631 shares of the Issuer's common stock at a weighted average sale price of $0.579. This transaction was executed in multiple trades at prices ranging from $0.50 to $0.73. The reporting person hereby undertakes to provide, upon request of the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. (F8) Mr. Chan is, personally and through an entity he controls, the majority shareholder of Alset Inc., and the Chairman and Chief Executive Officer of Alset Inc. Alset International Limited is a majority owned subsidiary of Alset Inc. Mr. Chan now may be deemed to be the beneficial owner of the 351,555 shares of common stock held by Alset International Limited. |
| 6 | Common | Common stock | 2025-04-03 | S | D | 273,286 | $0.78 | 180,000 | I See footnote | — | — | (F6) On April 3, 2025, Global Biomedical Pte. Ltd. sold 273,286 shares of the Issuer's common stock at a weighted average sale price of $0.779. This transaction was executed in multiple trades at prices ranging from $0.75 to $0.84. The reporting person hereby undertakes to provide, upon request of the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. (F8) Mr. Chan is, personally and through an entity he controls, the majority shareholder of Alset Inc., and the Chairman and Chief Executive Officer of Alset Inc. Alset International Limited is a majority owned subsidiary of Alset Inc. Mr. Chan now may be deemed to be the beneficial owner of the 351,555 shares of common stock held by Alset International Limited. |
| 7 | Common | Common stock | 2025-04-04 | S | D | 180,000 | $0.96 | 0 | I See footnote | — | — | (F7) On April 4, 2025, Global Biomedical Pte. Ltd. sold 180,000 shares of the Issuer's common stock at a weighted average sale price of $0.96 This transaction was executed in multiple trades at prices ranging from $0.93 to $0.997. The reporting person hereby undertakes to provide, upon request of the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. (F8) Mr. Chan is, personally and through an entity he controls, the majority shareholder of Alset Inc., and the Chairman and Chief Executive Officer of Alset Inc. Alset International Limited is a majority owned subsidiary of Alset Inc. Mr. Chan now may be deemed to be the beneficial owner of the 351,555 shares of common stock held by Alset International Limited. |